BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23468990)

  • 1. Delineating the cytogenomic and epigenomic landscapes of glioma stem cell lines.
    Baronchelli S; Bentivegna A; Redaelli S; Riva G; Butta V; Paoletta L; Isimbaldi G; Miozzo M; Tabano S; Daga A; Marubbi D; Cattaneo M; Biunno I; Dalprà L
    PLoS One; 2013; 8(2):e57462. PubMed ID: 23468990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
    Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
    BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells.
    Ozawa Y; Yamamuro S; Sano E; Tatsuoka J; Hanashima Y; Yoshimura S; Sumi K; Hara H; Nakayama T; Suzuki Y; Yoshino A
    Biochem Biophys Res Commun; 2020 Apr; 524(3):723-729. PubMed ID: 32035622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
    Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
    Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence.
    Baysan M; Woolard K; Cam MC; Zhang W; Song H; Kotliarova S; Balamatsias D; Linkous A; Ahn S; Walling J; Belova GI; Fine HA
    Int J Cancer; 2017 Nov; 141(10):2002-2013. PubMed ID: 28710771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells enhance stem-like properties and conditional malignancy in gliomas.
    Irvin DK; Jouanneau E; Duvall G; Zhang XX; Zhai Y; Sarayba D; Seksenyan A; Panwar A; Black KL; Wheeler CJ
    PLoS One; 2010 Jun; 5(6):e10974. PubMed ID: 20539758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human cytomegalovirus gene expression in long-term infected glioma stem cells.
    Fiallos E; Judkins J; Matlaf L; Prichard M; Dittmer D; Cobbs C; Soroceanu L
    PLoS One; 2014; 9(12):e116178. PubMed ID: 25549333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Glioma Stem Cell Model in the Era of Single-Cell Genomics.
    Suvà ML; Tirosh I
    Cancer Cell; 2020 May; 37(5):630-636. PubMed ID: 32396858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
    Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA
    Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
    Wakimoto H; Mohapatra G; Kanai R; Curry WT; Yip S; Nitta M; Patel AP; Barnard ZR; Stemmer-Rachamimov AO; Louis DN; Martuza RL; Rabkin SD
    Neuro Oncol; 2012 Feb; 14(2):132-44. PubMed ID: 22067563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QKI deficiency maintains glioma stem cell stemness by activating the SHH/GLI1 signaling pathway.
    Han B; Wang R; Chen Y; Meng X; Wu P; Li Z; Duan C; Li Q; Li Y; Zhao S; Jiang C; Cai J
    Cell Oncol (Dordr); 2019 Dec; 42(6):801-813. PubMed ID: 31292920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
    Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
    Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell signature in glioblastoma: therapeutic development for a moving target.
    Nakano I
    J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
    Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
    Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NT5DC2 promotes tumorigenicity of glioma stem-like cells by upregulating fyn.
    Guo S; Ran H; Xiao D; Huang H; Mi L; Wang X; Chen L; Li D; Zhang S; Han Q; Zhou T; Li A; Man J
    Cancer Lett; 2019 Jul; 454():98-107. PubMed ID: 30978441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines.
    Roversi G; Pfundt R; Moroni RF; Magnani I; van Reijmersdal S; Pollo B; Straatman H; Larizza L; Schoenmakers EF
    Oncogene; 2006 Mar; 25(10):1571-83. PubMed ID: 16247447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.